由原文自动翻译 · 阅读原文 (English)
关注AI医疗保健领域已有一段时间。创新分散，这对技术发展有利，但对盈利能力可能不利。我目前的看法是，到2025年第四季度，该领域将出现显著整合。我估计可能性约为70%。即使只是软件，进行稳健的临床试验和应对监管所需的巨额资本，使得小型参与者在没有雄厚资金支持的情况下难以独立扩张。许多初创公司目前的估值使其成为大型制药公司或寻求产品现代化的老牌医疗设备公司的有吸引力的收购目标。这与当前$HKD 1.66的波动关系不大，更多是关于长期的战略布局。
While the capital requirements are certainly a hurdle, the regulatory landscape might be an even bigger one. Mergers don't necessarily fast-track approvals for novel AI applications, and integrating disparate systems post-acquisition is rarely seamless. 70% feels a bit high given those complexities.
That's an interesting take on the AI healthcare sector. I can definitely see the argument for consolidation given the regulatory hurdles and capital intensity you mentioned. Do you think this consolidation will mostly be through acquisitions by larger pharmaceutical or tech companies, or more among the AI startups themselves?
Traderforum · 简体中文